Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 73 to 84 of 84 entries
Sorted by: Best Match Show Resources per page
Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.

Stem cell investigation

Jørgensen NG, Ahmad SM, Abildgaard N, Straten PT, Svane IM, Andersen MH, Knudsen LM.
PMID: 28078275
Stem Cell Investig. 2016 Dec 23;3:95. doi: 10.21037/sci.2016.11.09. eCollection 2016.

The B-cell lymphoma-2 (Bcl-2) family of proteins play a crucial role in multiple myeloma (MM), contributing to lacking apoptosis which is a hallmark of the disease. This makes the Bcl-2 proteins interesting targets for therapeutic peptide vaccination. We report...

Cite
Jørgensen NG, Ahmad SM, Abildgaard N, et al. Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial. Stem Cell Investig. 2016;3:95doi: 10.21037/sci.2016.11.09.
Jørgensen, N. G., Ahmad, S. M., Abildgaard, N., Straten, P. T., Svane, I. M., Andersen, M. H., & Knudsen, L. M. (2016). Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial. Stem cell investigation, 395. https://doi.org/10.21037/sci.2016.11.09
Jørgensen, Nicolai Grønne, et al. "Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial." Stem cell investigation vol. 3 (2016): 95. doi: https://doi.org/10.21037/sci.2016.11.09
Jørgensen NG, Ahmad SM, Abildgaard N, Straten PT, Svane IM, Andersen MH, Knudsen LM. Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial. Stem Cell Investig. 2016 Dec 23;3:95. doi: 10.21037/sci.2016.11.09. eCollection 2016. PMID: 28078275; PMCID: PMC5222710.
Copy Download .nbib Format: NLM
Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation.

OncoTargets and therapy

Andersen MN, Ludvigsen M, Abildgaard N, Petruskevicius I, Hjortebjerg R, Bjerre M, Honoré B, Møller HJ, Andersen NF.
PMID: 28435287
Onco Targets Ther. 2017 Apr 04;10:1977-1982. doi: 10.2147/OTT.S124321. eCollection 2017.

Galectin-1 (Gal-1) is known to regulate cell signaling within the immune system and may be a target for new anticancer immune therapy. In patients with chronic lymphocytic leukemia (CLL) and classical Hodgkin lymphoma (cHL), high levels of Gal-1 within...

Cite
Andersen MN, Ludvigsen M, Abildgaard N, et al. Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation. Onco Targets Ther. 2017;10:1977-1982doi: 10.2147/OTT.S124321.
Andersen, M. N., Ludvigsen, M., Abildgaard, N., Petruskevicius, I., Hjortebjerg, R., Bjerre, M., Honoré, B., Møller, H. J., & Andersen, N. F. (2017). Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation. OncoTargets and therapy, 101977-1982. https://doi.org/10.2147/OTT.S124321
Andersen, Morten Nørgaard, et al. "Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation." OncoTargets and therapy vol. 10 (2017): 1977-1982. doi: https://doi.org/10.2147/OTT.S124321
Andersen MN, Ludvigsen M, Abildgaard N, Petruskevicius I, Hjortebjerg R, Bjerre M, Honoré B, Møller HJ, Andersen NF. Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation. Onco Targets Ther. 2017 Apr 04;10:1977-1982. doi: 10.2147/OTT.S124321. eCollection 2017. PMID: 28435287; PMCID: PMC5388249.
Copy Download .nbib Format: NLM
How to Measure the Intervention Process? An Assessment of Qualitative and Quantitative Approaches to Data Collection in the Process Evaluation of Organizational Interventions.

Frontiers in psychology

Abildgaard JS, Saksvik PØ, Nielsen K.
PMID: 27713707
Front Psychol. 2016 Sep 22;7:1380. doi: 10.3389/fpsyg.2016.01380. eCollection 2016.

Organizational interventions aiming at improving employee health and wellbeing have proven to be challenging to evaluate. To analyze intervention processes two methodological approaches have widely been used: quantitative (often questionnaire data), or qualitative (often interviews). Both methods are established...

Cite
Abildgaard JS, Saksvik PØ, Nielsen K. How to Measure the Intervention Process? An Assessment of Qualitative and Quantitative Approaches to Data Collection in the Process Evaluation of Organizational Interventions. Front Psychol. 2016;7:1380doi: 10.3389/fpsyg.2016.01380.
Abildgaard, J. S., Saksvik, P. �. �., & Nielsen, K. (2016). How to Measure the Intervention Process? An Assessment of Qualitative and Quantitative Approaches to Data Collection in the Process Evaluation of Organizational Interventions. Frontiers in psychology, 71380. https://doi.org/10.3389/fpsyg.2016.01380
Abildgaard, Johan S, et al. "How to Measure the Intervention Process? An Assessment of Qualitative and Quantitative Approaches to Data Collection in the Process Evaluation of Organizational Interventions." Frontiers in psychology vol. 7 (2016): 1380. doi: https://doi.org/10.3389/fpsyg.2016.01380
Abildgaard JS, Saksvik PØ, Nielsen K. How to Measure the Intervention Process? An Assessment of Qualitative and Quantitative Approaches to Data Collection in the Process Evaluation of Organizational Interventions. Front Psychol. 2016 Sep 22;7:1380. doi: 10.3389/fpsyg.2016.01380. eCollection 2016. PMID: 27713707; PMCID: PMC5031711.
Copy Download .nbib Format: NLM
Cardiovascular mortality after bilateral oophorectomy: a prospective cohort study.

Menopause (New York, N.Y.)

Olesen CS, Koch T, Uldbjerg CS, Gregersen LS, Christensen J, Dehlendorff C, Priskorn L, Wilson LF, Lim YH, Jørgensen JT, Andersen ZJ, Juul A, Abildgaard J, Hickey M, Bräuner EV.
PMID: 34726195
Menopause. 2021 Nov 01;29(1):28-34. doi: 10.1097/GME.0000000000001873.

OBJECTIVES: Bilateral oophorectomy permanently reduces endogenous estrogen exposure and may increase cardiovascular mortality in women. This study aimed to investigate the association between bilateral oophorectomy and cardiovascular mortality and whether this association was conditional on hysterectomy or on the...

Cite
Olesen CS, Koch T, Uldbjerg CS, et al. Cardiovascular mortality after bilateral oophorectomy: a prospective cohort study. Menopause. 2021;29(1):28-34doi: 10.1097/GME.0000000000001873.
Olesen, C. S., Koch, T., Uldbjerg, C. S., Gregersen, L. S., Christensen, J., Dehlendorff, C., Priskorn, L., Wilson, L. F., Lim, Y. H., Jørgensen, J. T., Andersen, Z. J., Juul, A., Abildgaard, J., Hickey, M., & Bräuner, E. V. (2021). Cardiovascular mortality after bilateral oophorectomy: a prospective cohort study. Menopause (New York, N.Y.), 29(1), 28-34. https://doi.org/10.1097/GME.0000000000001873
Olesen, Cathrine S, et al. "Cardiovascular mortality after bilateral oophorectomy: a prospective cohort study." Menopause (New York, N.Y.) vol. 29,1 (2021): 28-34. doi: https://doi.org/10.1097/GME.0000000000001873
Olesen CS, Koch T, Uldbjerg CS, Gregersen LS, Christensen J, Dehlendorff C, Priskorn L, Wilson LF, Lim YH, Jørgensen JT, Andersen ZJ, Juul A, Abildgaard J, Hickey M, Bräuner EV. Cardiovascular mortality after bilateral oophorectomy: a prospective cohort study. Menopause. 2021 Nov 01;29(1):28-34. doi: 10.1097/GME.0000000000001873. PMID: 34726195.
Copy Download .nbib Format: NLM
Circulating trefoil factors in relation to lung cancer, age and lung function: a cross-sectional study in patients referred for suspected lung cancer.

Scandinavian journal of clinical and laboratory investigation

Samson MH, Abildgaard AM, Espelund U, Rasmussen TR, Folkersen B, Frystyk J, Nexo E.
PMID: 34242119
Scand J Clin Lab Invest. 2021 Oct;81(6):446-450. doi: 10.1080/00365513.2021.1943757. Epub 2021 Jul 09.

The trefoil factor family proteins: TFF1, TFF2 and TFF3 are secreted by epithelial cells in the respiratory tract. Here, we explore circulating concentrations of the trefoil factors in relation to lung cancer, age and lung function. We included 751...

Cite
Samson MH, Abildgaard AM, Espelund U, et al. Circulating trefoil factors in relation to lung cancer, age and lung function: a cross-sectional study in patients referred for suspected lung cancer. Scand J Clin Lab Invest. 2021;81(6):446-450doi: 10.1080/00365513.2021.1943757.
Samson, M. H., Abildgaard, A. M., Espelund, U., Rasmussen, T. R., Folkersen, B., Frystyk, J., & Nexo, E. (2021). Circulating trefoil factors in relation to lung cancer, age and lung function: a cross-sectional study in patients referred for suspected lung cancer. Scandinavian journal of clinical and laboratory investigation, 81(6), 446-450. https://doi.org/10.1080/00365513.2021.1943757
Samson, Mie H, et al. "Circulating trefoil factors in relation to lung cancer, age and lung function: a cross-sectional study in patients referred for suspected lung cancer." Scandinavian journal of clinical and laboratory investigation vol. 81,6 (2021): 446-450. doi: https://doi.org/10.1080/00365513.2021.1943757
Samson MH, Abildgaard AM, Espelund U, Rasmussen TR, Folkersen B, Frystyk J, Nexo E. Circulating trefoil factors in relation to lung cancer, age and lung function: a cross-sectional study in patients referred for suspected lung cancer. Scand J Clin Lab Invest. 2021 Oct;81(6):446-450. doi: 10.1080/00365513.2021.1943757. Epub 2021 Jul 09. PMID: 34242119.
Copy Download .nbib Format: NLM
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.

The Lancet. Haematology

Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos MV, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos MA, Gay F, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hajek R, Zojer N, Kastritis E, Broijl A, Schjesvold F, Boccadoro M, Terpos E.
PMID: 34756169
Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.

Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for infections and infection-related mortality. The risk for infection with SARS-CoV-2 virus and resulting mortality is also increased, emphasising the importance of protecting patients by...

Cite
Ludwig H, Sonneveld P, Facon T, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021;8(12):e934-e946doi: 10.1016/S2352-3026(21)00278-7.
Ludwig, H., Sonneveld, P., Facon, T., San-Miguel, J., Avet-Loiseau, H., Mohty, M., Mateos, M. V., Moreau, P., Cavo, M., Pawlyn, C., Zweegman, S., Engelhardt, M., Driessen, C., Cook, G., Dimopoulos, M. A., Gay, F., Einsele, H., Delforge, M., Caers, J., Weisel, K., Jackson, G., Garderet, L., van de Donk, N., Leleu, X., Goldschmidt, H., Beksac, M., Nijhof, I., Schreder, M., Abildgaard, N., Hajek, R., Zojer, N., Kastritis, E., Broijl, A., Schjesvold, F., Boccadoro, M., & Terpos, E. (2021). COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. The Lancet. Haematology, 8(12), e934-e946. https://doi.org/10.1016/S2352-3026(21)00278-7
Ludwig, Heinz, et al. "COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network." The Lancet. Haematology vol. 8,12 (2021): e934-e946. doi: https://doi.org/10.1016/S2352-3026(21)00278-7
Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos MV, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos MA, Gay F, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hajek R, Zojer N, Kastritis E, Broijl A, Schjesvold F, Boccadoro M, Terpos E. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28. PMID: 34756169; PMCID: PMC8553271.
Copy Download .nbib Format: NLM
Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly.

Clinica chimica acta; international journal of clinical chemistry

Abildgaard A, Knudsen CS, Hoejskov CS, Greibe E, Parkner T.
PMID: 34942168
Clin Chim Acta. 2022 Jan 15;525:62-68. doi: 10.1016/j.cca.2021.12.015. Epub 2021 Dec 21.

BACKGROUND: Plasma/serum vitamin B12 (B12) is often used to screen for B12 deficiency complemented with analysis of methylmalonic acid (MMA) in case of low B12. The concentration of both analytes likely depends on age, and we, therefore, aimed at...

Cite
Abildgaard A, Knudsen CS, Hoejskov CS, et al. Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly. Clin Chim Acta. 2021;525:62-68doi: 10.1016/j.cca.2021.12.015.
Abildgaard, A., Knudsen, C. S., Hoejskov, C. S., Greibe, E., & Parkner, T. (2022). Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly. Clinica chimica acta; international journal of clinical chemistry, 52562-68. https://doi.org/10.1016/j.cca.2021.12.015
Abildgaard, Anders, et al. "Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly." Clinica chimica acta; international journal of clinical chemistry vol. 525 (2022): 62-68. doi: https://doi.org/10.1016/j.cca.2021.12.015
Abildgaard A, Knudsen CS, Hoejskov CS, Greibe E, Parkner T. Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly. Clin Chim Acta. 2022 Jan 15;525:62-68. doi: 10.1016/j.cca.2021.12.015. Epub 2021 Dec 21. PMID: 34942168.
Copy Download .nbib Format: NLM
Correlation of whole-bone marrow dual-time-point .

American journal of nuclear medicine and molecular imaging

Zirakchian Zadeh M, Raynor WY, Østergaard B, Hess S, Yellanki DP, Ayubcha C, Mehdizadeh Seraj S, Acosta-Montenegro O, Borja AJ, Gerke O, Werner TJ, Zhuang H, Revheim ME, Abildgaard N, Høilund-Carlsen PF, Alavi A.
PMID: 33224622
Am J Nucl Med Mol Imaging. 2020 Oct 15;10(5):257-264. eCollection 2020.

The practical application of dual-time-point-imaging (DTPI) technique still remains controversial. One of the issues is that current parameters of DTPI quantification suffer from some deficiencies, mainly limited sampling of the diseased sites by confining measurements to specific locations. We...

Cite
Zirakchian Zadeh M, Raynor WY, Østergaard B, et al. Correlation of whole-bone marrow dual-time-point . Am J Nucl Med Mol Imaging. 2020;10(5):257-264
Zirakchian Zadeh, M., Raynor, W. Y., Østergaard, B., Hess, S., Yellanki, D. P., Ayubcha, C., Mehdizadeh Seraj, S., Acosta-Montenegro, O., Borja, A. J., Gerke, O., Werner, T. J., Zhuang, H., Revheim, M. E., Abildgaard, N., Høilund-Carlsen, P. F., & Alavi, A. (2020). Correlation of whole-bone marrow dual-time-point . American journal of nuclear medicine and molecular imaging, 10(5), 257-264.
Zirakchian Zadeh, Mahdi, et al. "Correlation of whole-bone marrow dual-time-point ." American journal of nuclear medicine and molecular imaging vol. 10,5 (2020): 257-264.
Zirakchian Zadeh M, Raynor WY, Østergaard B, Hess S, Yellanki DP, Ayubcha C, Mehdizadeh Seraj S, Acosta-Montenegro O, Borja AJ, Gerke O, Werner TJ, Zhuang H, Revheim ME, Abildgaard N, Høilund-Carlsen PF, Alavi A. Correlation of whole-bone marrow dual-time-point . Am J Nucl Med Mol Imaging. 2020 Oct 15;10(5):257-264. eCollection 2020. PMID: 33224622; PMCID: PMC7675111.
Copy Download .nbib Format: NLM
Assessment of atherosclerosis in multiple myeloma and smoldering myeloma patients using .

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Arani LS, Zirakchian Zadeh M, Saboury B, Revheim ME, Øestergaard B, Borja AJ, Samadi Samarin D, Mehdizadeh Seraj S, Kalbush E, Ayubcha C, Morris MA, Werner TJ, Abildgaard N, Høilund-Carlsen PF, Alavi A.
PMID: 33389640
J Nucl Cardiol. 2021 Jan 03; doi: 10.1007/s12350-020-02446-0. Epub 2021 Jan 03.

BACKGROUND: To compare the NaF uptake in the thoracic aorta and whole heart, as an early indicator of atherosclerosis, in multiple myeloma (MM) and smoldering multiple myeloma (SMM) patients with a healthy control (HC) group.METHODS: Forty-four untreated myeloma patients...

Cite
Arani LS, Zirakchian Zadeh M, Saboury B, et al. Assessment of atherosclerosis in multiple myeloma and smoldering myeloma patients using . J Nucl Cardiol. 2021;doi: 10.1007/s12350-020-02446-0.
Arani, L. S., Zirakchian Zadeh, M., Saboury, B., Revheim, M. E., Øestergaard, B., Borja, A. J., Samadi Samarin, D., Mehdizadeh Seraj, S., Kalbush, E., Ayubcha, C., Morris, M. A., Werner, T. J., Abildgaard, N., Høilund-Carlsen, P. F., & Alavi, A. (2021). Assessment of atherosclerosis in multiple myeloma and smoldering myeloma patients using . Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, . https://doi.org/10.1007/s12350-020-02446-0
Arani, Leila S, et al. "Assessment of atherosclerosis in multiple myeloma and smoldering myeloma patients using ." Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. (2021). doi: https://doi.org/10.1007/s12350-020-02446-0
Arani LS, Zirakchian Zadeh M, Saboury B, Revheim ME, Øestergaard B, Borja AJ, Samadi Samarin D, Mehdizadeh Seraj S, Kalbush E, Ayubcha C, Morris MA, Werner TJ, Abildgaard N, Høilund-Carlsen PF, Alavi A. Assessment of atherosclerosis in multiple myeloma and smoldering myeloma patients using . J Nucl Cardiol. 2021 Jan 03; doi: 10.1007/s12350-020-02446-0. Epub 2021 Jan 03. PMID: 33389640.
Copy Download .nbib Format: NLM
The activated partial thromboplastin time may not reveal even severe fibrinogen deficiency.

Clinical chemistry and laboratory medicine

Abildgaard A, Hvas AM.
PMID: 33544482
Clin Chem Lab Med. 2021 Jan 28;59(7):e297-e300. doi: 10.1515/cclm-2020-1626. Print 2021 Jun 25.

No abstract available.

Cite
Abildgaard A, Hvas AM. The activated partial thromboplastin time may not reveal even severe fibrinogen deficiency. Clin Chem Lab Med. 2021;59(7):e297-e300doi: 10.1515/cclm-2020-1626.
Abildgaard, A., & Hvas, A. M. (2021). The activated partial thromboplastin time may not reveal even severe fibrinogen deficiency. Clinical chemistry and laboratory medicine, 59(7), e297-e300. https://doi.org/10.1515/cclm-2020-1626
Abildgaard, Anders, and Hvas, Anne-Mette. "The activated partial thromboplastin time may not reveal even severe fibrinogen deficiency." Clinical chemistry and laboratory medicine vol. 59,7 (2021): e297-e300. doi: https://doi.org/10.1515/cclm-2020-1626
Abildgaard A, Hvas AM. The activated partial thromboplastin time may not reveal even severe fibrinogen deficiency. Clin Chem Lab Med. 2021 Jan 28;59(7):e297-e300. doi: 10.1515/cclm-2020-1626. Print 2021 Jun 25. PMID: 33544482.
Copy Download .nbib Format: NLM
Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial.

Medicine and science in sports and exercise

Abildgaard J, Johansen MY, Skov-Jeppesen K, Andersen LB, Karstoft K, Hansen KB, Hartmann B, Holst JJ, Pedersen BK, Ried-Larsen M.
PMID: 34431828
Med Sci Sports Exerc. 2022 Jan 01;54(1):38-46. doi: 10.1249/MSS.0000000000002776.

INTRODUCTION/PURPOSE: The increased risk of fractures with type 2 diabetes (T2D) is suggested to be caused by decreased bone turnover. Current international guidelines recommend lifestyle modifications, including exercise, as first-line treatment for T2D. The aim of this study was...

Cite
Abildgaard J, Johansen MY, Skov-Jeppesen K, et al. Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Med Sci Sports Exerc. 2022;54(1):38-46doi: 10.1249/MSS.0000000000002776.
Abildgaard, J., Johansen, M. Y., Skov-Jeppesen, K., Andersen, L. B., Karstoft, K., Hansen, K. B., Hartmann, B., Holst, J. J., Pedersen, B. K., & Ried-Larsen, M. (2022). Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Medicine and science in sports and exercise, 54(1), 38-46. https://doi.org/10.1249/MSS.0000000000002776
Abildgaard, Julie, et al. "Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial." Medicine and science in sports and exercise vol. 54,1 (2022): 38-46. doi: https://doi.org/10.1249/MSS.0000000000002776
Abildgaard J, Johansen MY, Skov-Jeppesen K, Andersen LB, Karstoft K, Hansen KB, Hartmann B, Holst JJ, Pedersen BK, Ried-Larsen M. Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Med Sci Sports Exerc. 2022 Jan 01;54(1):38-46. doi: 10.1249/MSS.0000000000002776. PMID: 34431828.
Copy Download .nbib Format: NLM
Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial.

Medicine and science in sports and exercise

Abildgaard J, Johansen MY, Skov-Jeppesen K, Andersen LB, Karstoft K, Hansen KB, Hartmann B, Holst JJ, Pedersen BK, Ried-Larsen M.
PMID: 34431828
Med Sci Sports Exerc. 2022 Jan 01;54(1):38-46. doi: 10.1249/MSS.0000000000002776.

INTRODUCTION/PURPOSE: The increased risk of fractures with type 2 diabetes (T2D) is suggested to be caused by decreased bone turnover. Current international guidelines recommend lifestyle modifications, including exercise, as first-line treatment for T2D. The aim of this study was...

Cite
Abildgaard J, Johansen MY, Skov-Jeppesen K, et al. Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Med Sci Sports Exerc. 2022;54(1):38-46doi: 10.1249/MSS.0000000000002776.
Abildgaard, J., Johansen, M. Y., Skov-Jeppesen, K., Andersen, L. B., Karstoft, K., Hansen, K. B., Hartmann, B., Holst, J. J., Pedersen, B. K., & Ried-Larsen, M. (2022). Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Medicine and science in sports and exercise, 54(1), 38-46. https://doi.org/10.1249/MSS.0000000000002776
Abildgaard, Julie, et al. "Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial." Medicine and science in sports and exercise vol. 54,1 (2022): 38-46. doi: https://doi.org/10.1249/MSS.0000000000002776
Abildgaard J, Johansen MY, Skov-Jeppesen K, Andersen LB, Karstoft K, Hansen KB, Hartmann B, Holst JJ, Pedersen BK, Ried-Larsen M. Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Med Sci Sports Exerc. 2022 Jan 01;54(1):38-46. doi: 10.1249/MSS.0000000000002776. PMID: 34431828.
Copy Download .nbib Format: NLM
Showing 73 to 84 of 84 entries